Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Beyond Exhaustion: The PDL1-PD1 Axis Shapes the Classical Hodgkin Lymphoma Microenvironment

Joseph G Taylor, MBBS, BSc, Andrew James Clear, BSc, Edward Truelove, MBBS, BSc, MRCP, FRCPath, Mariarita Calaminici, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 658.

https://doi.org/10.1182/blood-2019-125247

Published: 2019

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Anthony R. Mato, MDMSCE, Lindsey E. Roeker, MD, Toby A. Eyre, MBBChir, MRCP, Ryan Jacobs, MD, Brian T. Hill, MD, Nicole Lamanna, MD, Danielle M. Brander, MD, Mazyar Shadman, MD, Chaitra Ujjani, MD, Maryam Yazdy, MD, Guilherme Fleury Perini, MD, Javier Pinilla Ibarz, MD PhD, Jacqueline C Barrientos, MD, Alan Skarbnik, MD, Pallawi Torka, MD, Jeffrey J Pu, MD PhD, John M. Pagel, MD PhD DSc, Satyen Gohil, BSc, MBBS, MRCP, FRCPath, Bita Fakhri, MDMPH, Michael Y. Choi, MD, Catherine C. Coombs, MD, Joanna Rhodes, MD, Paul M. Barr, MD, Craig A. Portell, MD, Helen Parry, MB ChB, MRCP, PhD, Christine Ann Garcia, MD MPH, Kate J Whitaker, BA, Allison M. Winter, MD, Andrea Sitlinger, MD, Sirin Khajavian, MD, Ariel F Grajales-Cruz, MD, Krista Isaac, DO, MS, Pratik Shah, Othman S. Akhtar, MD, Rachael Pocock, MD, Kentson Lam, MD PhD, Timothy J Voorhees, MD, Stephen J. Schuster, MD, Thomas David Rodgers, MD, Nicolas Martinez-Calle, MD MSc, Talha Munir, MD, Erica B Bhavsar, BS, Neil Bailey, MSc, Jason C. Lee, MD, Hanna Weissbrot, BS, Chadi Nabhan, MDMBA, FACP, Julie Goodfriend, Amber C. King, PharmD, BCOP, Andrew D. Zelenetz, MD PhD, Colleen Dorsey, BSN, RN, Kayla Bigelow, Bruce D. Cheson, MD, Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, John N. Allan, MD

Blood (2019) 134 (Supplement_1): 502.

https://doi.org/10.1182/blood-2019-123747

Published: 2019

Journal Articles

PD-1 Inhibitor Combined with Chemotherapy As a Salvage Therapy for Refractory DLBCL

Xin Li, Rui Zhang, Qing Li, Juan Mu, Yedi Pu, Yili Jiang, Qi Deng

Blood (2019) 134 (Supplement_1): 5357.

https://doi.org/10.1182/blood-2019-128035

Published: 2019

Journal Articles

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Jakub Svoboda, MD, Hatcher J. Ballard, BS, Elise A. Chong, MD, Meredith I LaRose, MD, Steven M. Bair, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Elizabeth Weber, BSN, RN, Chase Walling, BS, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 1606.

https://doi.org/10.1182/blood-2019-131482

Published: 2019

Journal Articles

Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement

Zachary AK Frosch, MD, Sunita Dwivedy Nasta, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Elise A. Chong, MD, Emily C. Ayers, MD, Joanna M Rhodes, MD, Alexa Koike, Jennifer J.D. Morrissette, PhD, Daniel J. Landsburg, MD

Blood (2019) 134 (Supplement_1): 1607.

https://doi.org/10.1182/blood-2019-125944

Published: 2019

Journal Articles

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

John E. Godwin, MD, Carmen Ballesteros-Merino, PhD, Nikhil Lonberg, Shawn Jensen, PhD, Tarsem Moudgil, Carlo B Bifulco, MD, Jon Wigginton, MD, John Muth, MS, Jan K Davidson-Moncada, MD PhD, Bernard Fox, PhD

Blood (2019) 134 (Supplement_1): 1410.

https://doi.org/10.1182/blood-2019-128485

Published: 2019

Journal Articles

Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

Shelley Herbrich, MS, Antonio Cavazos, Cora Marie C Cheung, BSN, Lynette Alexander-Williams, Nicholas J. Short, MD, Jairo Matthews, Naval G. Daver, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1428.

https://doi.org/10.1182/blood-2019-128601

Published: 2019

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Sven de Vos, MD PhD, Gilles A. Salles, MD PhD, Wojciech Jurczak, MD PhD, Nishan Rajakumaraswamy, MD, Guan Xing, PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 4006.

https://doi.org/10.1182/blood-2019-121936

Published: 2019

Journal Articles

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Conrad-Amadeus Voltin, Jasmin Mettler, MD, Horst Mueller, PhD, Michael Fuchs, MD, Christian Baues, MD, Markus Dietlein, MD, Andreas Engert, MD, Peter Borchmann, MD PhD, Carsten Kobe, Paul J Bröckelmann, MD

Blood (2019) 134 (Supplement_1): 4020.

https://doi.org/10.1182/blood-2019-123641

Published: 2019

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma

Jason R. Westin, MD, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Hun Ju Lee, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Raphael E Steiner, MD, Sairah Ahmed, MD, Simrit Parmar, MBBS, Ranjit Nair, MBBS,MD, Rebecca Harrison, MD, Luis Fayad, MD

Blood (2019) 134 (Supplement_1): 4086.

https://doi.org/10.1182/blood-2019-131463

Published: 2019

Journal Articles

Efficacy and Safety of PD-1 Inhibitor Plus GVD Chemotherapy in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMLBCL)

Qian Mei, PhD, Wenying Zhang, MD, Yang Liu, MD, Qingming Yang, MD, John E.J. Rasko, MBBS, PhD, Weidong Han, PhD MD

Blood (2019) 134 (Supplement_1): 4072.

https://doi.org/10.1182/blood-2019-121768

Published: 2019

Journal Articles

Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial

Blood (2019) 134 (Supplement_1): 4103.

https://doi.org/10.1182/blood-2019-129107

Published: 2019

Journal Articles

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Sunita Dwivedy Nasta, MD, Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Daniel J. Landsburg, MD, Elise A. Chong, MD, Stefan K. Barta, MD MRCP, MS, Noelle V. Frey, MD, James N. Gerson, MD, Amit Maity, MD PhD, John Plastaras, MD, David L. Porter, MD, Marco Ruella, MD, Jakub Svoboda, MD, Hatcher J. Ballard, BS, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 4108.

https://doi.org/10.1182/blood-2019-131399

Published: 2019

Journal Articles

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Stefan K. Barta, MD MRCP, MS, Nathan H. Fowler, MD, Jasmine Zain, MD, Jia Ruan, MD PhD, Sonali M. Smith, MD, Stephen J. Schuster, MD, Sunita D Nasta, MD, Jakub Svoboda, MD, James N Gerson, MD, Daniel J. Landsburg, MD, Elise A. Chong, MD, Henry C. Fung, FRCP,MBBChir, Kerry S Campbell, PhD, Nadia Khan, MD, Richard I. Fisher, MD, Carlyn Rose Tan, MD

Blood (2019) 134 (Supplement_1): 4031.

https://doi.org/10.1182/blood-2019-125385

Published: 2019

Journal Articles

Highly Multiplexed Single Cell Spatial Analysis of the Tumor Microenvironment in Lymphoma Predicts Clinical Outcomes

Monirath Hav, PhD, Anthony Colombo, MS, Erik Gerdtsson, MS, Mohan Singh, PhD, Denaly Chen, MD, James Hicks, PhD, Peter Kuhn, PhD, Imran Siddiqi, MD PhD, Akil Merchant, MD

Blood (2019) 134 (Supplement_1): 2789.

https://doi.org/10.1182/blood-2019-130831

Published: 2019

Journal Articles

Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma

Theodora Anagnostou, MD, Zhi-Zhang Yang, MD, Hyojin Kim, PhD, Shahrzad Jalali, PhD, Jose C Villasboas, Hongyan Wu, PhD, Tammy Price-Troska, BS, Anne J Novak, PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 2790.

https://doi.org/10.1182/blood-2019-127757

Published: 2019

Journal Articles

Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients

Carrie I Ho, MD, Hatcher J. Ballard, BS, W. Tris Arscott, MD, Mitchell E. Hughes, PharmD, Abigail Doucette, MPH, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, James N. Gerson, MD, Amit Maity, MD PhD, Stephen J. Schuster, MD, Stefan K. Barta, MD MRCP, MS, John Plastaras, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 2905.

https://doi.org/10.1182/blood-2019-124195

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Beyond Exhaustion: The PDL1-PD1 Axis Shapes the Classical Hodgkin Lymphoma Microenvironment

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

PD-1 Inhibitor Combined with Chemotherapy As a Salvage Therapy for Refractory DLBCL

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma

Efficacy and Safety of PD-1 Inhibitor Plus GVD Chemotherapy in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMLBCL)

Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Highly Multiplexed Single Cell Spatial Analysis of the Tumor Microenvironment in Lymphoma Predicts Clinical Outcomes

Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma

Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only